M3 leukemia usually needs to take retinoic acid for 1.5~2 years, but the specific time of taking medication should also be combined with the patient’s condition, recovery and other comprehensive judgment, which varies from person to person.
M3 leukemia refers to acute promyelocytic leukemia, which is a type of acute leukemia with the best prognosis, and its treatment is mainly divided into induction, consolidation and maintenance therapy. Induction therapy lasts about 1 month; consolidation therapy lasts about 7 months; and maintenance therapy lasts a total of about 9 months. If a patient’s condition is severe or if symptoms are not relieved by taking the medication, the duration of taking retinoic acid may be extended.
Patients may experience adverse reactions such as conjunctivitis and hyperlipidemia while taking the drug. The drug is contraindicated in women during pregnancy and in those with severe liver or kidney impairment. If an allergic reaction is detected during the use of the drug, it should be discontinued.
Note that the drug should be used under the guidance of a doctor, avoid unauthorized use of the drug, so as not to cause adverse effects. If intolerable discomfort occurs during the use of the drug, it is recommended to consult a doctor in a timely manner, improve the relevant examination, clarify the cause of the disease and receive targeted treatment.